Study results presented during the 2021 ASCO Annual Meeting showed an association between increased prostate-specific antigen (PSA) screening and improved outcomes in younger African American patients.
In this video, lead study author Edmund M. Qiao, a medical student at the University of California San Diego, discusses how the results show that in younger African Americans, an increase in the frequency of PSA screening was linked to a nearly 25% reduction in prostate cancer–specific mortality and an approximately 40% lower risk of having metastatic disease at the time of a prostate cancer diagnosis. Based on their findings, the researchers recommend that younger African Americans begin having discussions early with their physicians regarding whether they need screening.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.